Expanded access to tipifarnib for certain cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This expanded access program provides tipifarnib to people with HRAS-mutated cancers or peripheral T-cell lymphoma who have no other standard treatment options and cannot join a clinical trial. The goal is to offer the drug when no satisfactory alternative exists.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a cancer with an HRAS mutation or peripheral T-cell lymphoma (PTCL).
- You have tried all standard treatments that could help, and they didn't work or caused serious side effects.
- No other treatment that is comparable or satisfactory is available for your condition.
- You cannot join any ongoing clinical study of tipifarnib, for example because of travel or other barriers.
- A Kura Oncology doctor confirms that you meet the medical criteria for receiving the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
This trial tests a combination of two drugs (tipifarnib and naxitamab) for children and young adults with neuroblastoma that has come back or hasn't responded to standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
This trial tests a new drug called retlirafusp alfa (a type of immunotherapy) combined with chemotherapy or another drug called fuzuloparib (a PARP inhibitor) for triple-negative breast cancer that is advanced or newly diagnosed at stage II-III. The goal is to see if this combination can shrink tumors or improve outcomes compared to standard treatments.
This trial tests a new drug called GFH276 for people with advanced solid tumors that have a RAS mutation. It aims to see if the drug is safe and effective against these tumors.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Hear when a new HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.